Table 2: Progression Cases (N = 4).
|
SN |
Year |
Age |
Stage |
Histology |
Chemotherapy |
Cycle |
site |
Primary surgery |
Note |
|
50 |
2013 |
17 |
IC1 |
Immature teratoma grade 2 |
none |
- |
right |
Right SO and appendectomy |
PFS 3 mosà pelvic recurrence à debulking tumor and BEP x6 cyclesà alive without disease DFS 103 mos, overall survival 109 mo |
|
52 |
2013 |
15 |
IV |
Yolk sac tumor |
BEP |
8 |
right |
Right SO and left cystectomy and omentectomy |
Progression after BEP x 8: liver & lung metastasis à TIP x 2 à PTx1 àifosfamide x 1 à progression à death (overall survival 16 mo) |
|
74 |
2010 |
18 |
IV |
Choriocarcinoma |
EMACO |
6 |
Left |
Left SO and omentectomy and appendectomy and PAN sampling |
EMACOx 6 àProgression (PFS 7 mos) à cisplatinand ifosfamide x 5 à paclitaxel x 1 à Act D and 5 FU x 1 à VAC x 1 à TAH and right SO (19/4/2011)à EMA/EP x 9 à TP/TE x1 à BEP x 2 à palliative treatment à death 5/7/2012 overall survival 28 mo |
|
110 |
2005 |
16 |
IV |
Yolk sac tumor |
BEP x 2 à EP x 11 |
12 |
right |
Right SO and appendectomy |
Progression after EP x 11 àifosfamide x 1 à EMA x 1 à single paclitaxel x 1 à palliative RT 25/1/2006 à VAC x 1 àDeath 4/7/2007,OS 30 mo (lung fibrosis after BEP x 2) |
PFS: Progression Free Survival; DFS: Disease Free Survival, mo: months; SO: Salpingo-Oophorectomy; PAN: Para Aortic Lymph Node; BEP: Bleomycin+Etoposide+Cisplatin; EMACO: Etoposide+ Methotrexate+ Actinomycin D + Cyclophosphamide + Vincristine; TIP: Paclitaxel + Ifosfamide + Cisplatin; PT: Paclitaxel+Carboplatin; Act D: Actinomycin D; EMA/EP: Etoposide+ Methotrexate+ Actinomycin D + Etoposide + Cisplatin; 5FU: fluorouracil; VAC: Vincristine+ Dactinomycin And+Cyclophosphamide; TP/TE: Paclitaxel+ Cisplatin/Paclitaxel+ Etoposide; TAH: Total Abdominal Hysterectomy; EP: Etoposide+Cisplatin; palliative RT: radiotherapy